Pipeline — registered trials by phase
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Danaher is lead sponsor; 0 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 25-NSE2026-09-3025-NSE
- 8-K2026-08-03Current report (material event)
- 8-K2026-07-21Current report (material event)
- 10-Q2026-07-21Quarterly report
- 11-K2026-06-1611-K
- S-82026-06-09Employee stock plan
- S-82026-06-09Employee stock plan
- 8-K2026-06-03Current report (material event)
- SD2026-05-12SD
- 8-K2026-05-07Current report (material event)
- CERT2026-04-30CERT
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- 8-A12B2026-04-298-A12B
- 8-K2026-04-29Current report (material event)
- 424B52026-04-23Prospectus (offering)
- FWP2026-04-22FWP
- 424B52026-04-22Prospectus (offering)
- 8-K2026-04-21Current report (material event)
- 10-Q2026-04-21Quarterly report
- 8-K2026-04-17Current report (material event)
- SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
- ARS2026-03-25Annual report to holders
- DEFA14A2026-03-25DEFA14A
- DEF 14A2026-03-25Proxy statement
- 25-NSE2026-03-1825-NSE
- DFAN14A2026-02-27DFAN14A
- 10-K2026-02-24Annual report
- DFAN14A2026-02-17DFAN14A
- 8-K2026-02-17Current report (material event)
- 8-K2026-02-10Current report (material event)
- SCHEDULE 13G/A2026-01-30SCHEDULE 13G/A
- 8-K2026-01-28Current report (material event)
- 8-K2026-01-12Current report (material event)
- 8-K2025-11-06Current report (material event)
- 10-Q2025-10-21Quarterly report
- 8-K2025-10-21Current report (material event)
- 8-K2025-09-10Current report (material event)
- 8-K2025-07-31Current report (material event)
- 8-K2025-07-24Current report (material event)
- 10-Q2025-07-22Quarterly report
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.